Integrated screening for Down's syndrome based on tests performed during the first and second trimesters

New England Journal of Medicine

Volumn 341, Issue 7, 1999, Pages 461-467

  Wald, N J ^a   Watt, H C ^a   Hackshaw, A K ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; ESTRIOL; INHIBIN A;

ADULT; ARTICLE; CHORION VILLUS SAMPLING; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DOWN SYNDROME; FEMALE; FETUS; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREDICTION; PRENATAL SCREENING; PRIORITY JOURNAL; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY;

ADOLESCENT; ADULT; ALPHA-FETOPROTEINS; CHORIONIC GONADOTROPIN; DOWN SYNDROME; ESTRIOL; FALSE POSITIVE REACTIONS; FEMALE; GENETIC SCREENING; HUMANS; INHIBINS; LIKELIHOOD FUNCTIONS; MATERNAL AGE; NECK; NORMAL DISTRIBUTION; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; RISK; SENSITIVITY AND SPECIFICITY;

EID: 0033549839     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199908123410701     Document Type: Article

References (27)

1. Wald NJ, Cuckle HS, Densem JW, et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988;297:883-7. [Erratum, BMJ 1988;297:1029.]
2. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down's syndrome. J Med Screen 1997;4:181-246. [Erratum, J Med Screen 1998;5:110, 166.]
3. Haddow JE, Palomaki GE, Knight GJ, Foster DL, Neveux LM. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A. J Med Screen 1998;5:115-9.
4. Pandya PP, Snijders RJM, Johnson SP, De Lourdes Brizot M, Nicolaides KH. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. Br J Obstet Gynaecol 1995;102:957-62.
5. Wald NJ, Hackshaw A. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn 1997;17:821-9.
6. Nielson JP. Assessment of fetal nuchal translucency test for Down's syndrome. Lancet 1997;350:754-5.
7. Nicolaides KH, Sebire NJ, Snijders RJM, Johnson S. Down's syndrome screening in the UK. Lancet 1996;347:906-7.
8. Hackshaw AK, Wald NJ, Haddow JE. Down's syndrome screening with nuchal translucency. Lancet 1996;348:1740.
9. Snijders RJM, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet 1998; 352:343-6.
10. Haddow JE. Antenatal screening for Down's syndrome: where are we and where next? Lancet 1998;352:336-7.
11. Haddow JE, Palomaki GE, Knight GJ, Williams J, Miller WA, Johnson A. Screening of maternal serum for fetal Down's syndrome in the first trimester. N Engl J Med 1998;338:955-61.
12. Nicolaides KH, Snijders RJM, Cuckle HS. Correct estimation of parameters for ultrasound nuchal translucency screening. Prenat Diagn 1998; 18:519-23.
13. Wald NJ, George L, Smith D, Densem JW, Petterson K. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. Br J Obstet Gynaecol 1996;103:407-12.
14. Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG. Prenatal screening for Down's syndrome using inhibin-A as a serum marker. Prenat Diagn 1996;16:143-53. [Erratum, Prenat Diagn 1997;17:285-90.]
15. Wald NJ, Densem JW, George L, et al. Inhibin-A in Down's syndrome pregnancies: revised estimate of standard deviation. Prenat Diagn 1997;17: 285-90.
16. Wald NJ, Densem JW, Smith D, Klee GG. Four marker serum screening for Down's syndrome. Prenat Diagn 1994;14:707-16.
17. Wald NJ, Cuckle HS, Densem JW, Kennard A, Smith D. Maternal serum screening for Down's syndrome: the effect of routine ultrasound scan determination of gestational age and adjustment for maternal weight. Br J Obstet Gynaecol 1992;99:144-9.
18. Wald NJ, Hackshaw AK, Huttly W, Kennard A. Empirical validation of risk screening for Down's syndrome. J Med Screen 1996;3:185-7.
19. De Biasio P, Siccardi M, Volpe G, Famularo L, Santi F, Canini S. First trimester screening for Down's syndrome using nuchal translucency measurement with free β-hCG and PAPP-A between 10 and 13 weeks of pregnancy: the combined test. Prenat Diagn 1999;19:360-3.
20. Lam YH, Lee CP, Sin SY, Wong HS, Tang R, Tang MHY. First trimester nuchal translucency and second trimester serum screening for fetal Down's syndrome. Ultrasound Obstet Gynecol 1998;12:Suppl 1:A62. abstract.
21. Brizot ML, Snijders RJM, Bersinger NA, Kuhn P, Nicolaides KH. Maternal serum pregnancy-associated plasma protein A and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy. Obstet Gynecol 1994;6:918-22.
22. Brizot ML, Snijders RJM, Butler J, Bersinger NA, Nicolaides KH. Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy. Br J Obstet Gynaecol 1995;102:127-32.
23. Noble PL, Abraha HD, Snijders RJM, Sherwood R, Nicolaides KH. Screening for fetal trisomy 21 in the first trimester of pregnancy: maternal serum free β-hCG and fetal nuchal translucency thickness. Ultrasound Obstet Gynecol 1995;6:390-5.
24. Cuckle HS, Wald NJ, Thompson SG. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 1987;94:387-402.
25. Royston P, Thompson SG. Model-based screening by risk with application to Down's syndrome. Stat Med 1992;11:257-68.
26. Canick JA, Rish S. The accuracy of assigned risks in maternal serum screening. Prenat Diagn 1998;18:413-5.
27. Onda T, Tanaka T, Takeda O, et al. Agreement between predicted risk and prevalence of Down syndrome in second-trimester triple-marker screening in Japan. Prenat Diagn 1998;18:956-8.